Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -2.45 is 18% below its 5-year average of -2.08, near the low end of its 5-year range (-2.45–0.01).
As of the fiscal period ended Tuesday, June 30, 2026. 8.15% below its 12-month average of -2.27.
Reported quarterly debt to equity ratio; no daily interpolation. Q3 FY2026 (2026-06-30): -2.45.
DEBT TO EQUITY RATIO
-2.45
DEBT TO EQUITY RATIO AVG TTM
-2.27
DEBT TO EQUITY RATIO AVG 3Y
-2.13
DEBT TO EQUITY RATIO AVG 5Y
-2.08
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-8.15%
CURRENT VS 3Y AVG
-14.81%
CURRENT VS 5Y AVG
-17.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 686 covered companies
CURRENT VS SECTOR MEDIAN
-2231.27%
vs the sector median at left
Embecta Corp.
Market Cap
$359.28M
Debt to Equity Ratio
-2.45
TTM Avg
-2.27
3Y Avg
-2.13
5Y Avg
-2.08
Market Cap
$359.09M
Debt to Equity Ratio
0.55
TTM Avg
2.43
3Y Avg
1.26
5Y Avg
0.85
Market Cap
$354.94M
Debt to Equity Ratio
0.03
TTM Avg
0.09
3Y Avg
0.09
5Y Avg
0.09
Market Cap
$363.70M
Debt to Equity Ratio
N/A
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$355.36M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.11
Market Cap
$352.95M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$351.67M
Debt to Equity Ratio
2.41
TTM Avg
0.38
3Y Avg
0.25
5Y Avg
0.25
Market Cap
$374.11M
Debt to Equity Ratio
0.40
TTM Avg
0.56
3Y Avg
1.08
5Y Avg
0.88
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Embecta Corp. (EMBC) | $359.28M | -2.45 | -2.27 | -2.13 | -2.08 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $359.09M | 0.55 | 2.43 | 1.26 | 0.85 |
| Ocugen, Inc. (OCGN)vs › | $357.76M | N/A | 0.64 | 0.35 | 0.27 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $354.94M | 0.03 | 0.09 | 0.09 | 0.09 |
| Opus Genetics, Inc. (IRD)vs › | $363.70M | N/A | 0.00 | 0.00 | 0.00 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.36M | 0.00 | 0.00 | 0.00 | 0.11 |
| Relmada Therapeutics, Inc. (RLMD)vs › | $352.95M | 0.00 | 0.00 | 0.00 | 0.00 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $351.67M | 2.41 | 0.38 | 0.25 | 0.25 |
| Canopy Growth Corporation (CGC)vs › | $374.11M | 0.40 | 0.56 | 1.08 | 0.88 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $381.24M | 0.13 | 0.12 | 0.17 | 0.17 |
Debt/Equity
-2.45
Current Ratio
1.68
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -2.45 |
| 2026-03-31 | -2.17 |
| 2025-12-31 | -2.27 |
| 2025-09-30 | -2.20 |
| 2025-06-30 | -2.24 |
| 2025-03-31 | -2.11 |
| 2024-12-31 | -2.05 |
| 2024-09-30 | -2.18 |
| 2024-06-30 | -2.16 |
| 2024-03-31 | -2.15 |
| 2023-12-31 | -2.06 |
| 2023-09-30 | -1.99 |
| 2023-06-30 | -2.03 |
| 2023-03-31 | -2.00 |
| 2022-12-31 | -1.96 |
| 2022-09-30 | -1.84 |
| 2022-06-30 | -1.94 |
| 2022-03-31 | -1.66 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.01 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.00 |
